# Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia

> **NCT00056433** · PHASE1 · COMPLETED · sponsor: **National Institutes of Health Clinical Center (CC)** · enrollment: 39 (actual)

## Conditions studied

- Sickle Cell Anemia

## Interventions

- **DRUG:** Hydroxyurea
- **DRUG:** L-Arginine
- **DRUG:** Sildenafil

## Key facts

- **NCT ID:** NCT00056433
- **Lead sponsor:** National Institutes of Health Clinical Center (CC)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-03-10
- **Primary completion:** 2006-12-27
- **Final completion:** 2006-12-27
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2019-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00056433

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00056433, "Evaluation of Hydroxyurea Plus L-arginine or Sildenafil to Treat Sickle Cell Anemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00056433. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*